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Abstract
Background: Inherited muscle diseases are a group of rare heterogeneous muscle conditions with great impact on
quality of life, for which variable prevalence has previously been reported, probably due to case selection bias. The
aim of this study is to estimate the overall and selective prevalence rates of inherited muscle diseases in a northern
Spanish region and to describe their demographic and genetic features. Retrospective identification of patients with
inherited muscle diseases between 2000 and 2015 from multiple data sources. Demographic and molecular data
were registered.
Results: On January 1, 2016, the overall prevalence of inherited muscle diseases was 59.00/ 100,000 inhabitants (CI
95%; 53.35–65.26). Prevalence was significantly greater in men (67.33/100,000) in comparison to women (50.80/100,
000) (p = 0.006). The highest value was seen in the age range between 45 and 54 (91.32/100,000) years. Myotonic
dystrophy type 1 was the most common condition (35.90/100,000), followed by facioscapulohumeral muscular
dystrophy (5.15/100,000) and limb-girdle muscular dystrophy type 2A (2.5/100,000).
Conclusions: Prevalence of inherited muscle diseases in Navarre is high in comparison with the data reported for
other geographical regions. Standard procedures and analyses of multiple data sources are needed for
epidemiological studies of this heterogeneous group of diseases.
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Background
Inherited muscle diseases (IMDs), defined as rare dis-
eases due to their low prevalence, make up a complex
group of clinically and genetically heterogeneous condi-
tions. IMDs can appear at any age and are characterized
by a variety of symptoms including progressive muscle
weakness, cramps, stiffness, joint deformities, chronic
pain, respiratory and/or cardiac involvement, and a
broad range of cognitive impairments [1, 2]. These path-
ologies cause variable degrees of disability in patients
and have a major impact on the quality of life and health
budgets worldwide [3]. The number of subjects with this
type of condition is expected to increase due to better
prevention of complications and genetic diagnosis ad-
vances, thus, prevalence data are essential for future
budget estimates.
Despite the relevance of identifying these data only
few epidemiological studies include all types of IMDs,
and their methodology and results vary widely [4–14].
There seems to be regional differences concerning the
prevalence of these conditions and potential ethnic dif-
ferences are not fully understood.
For comparison purposes, standardized procedures for
conducting epidemiological studies in this field have
been proposed [15]. In Spain, there is little published in-
formation about IMDs. Most studies have been per-
formed at regional level, focusing on a certain type of
IMD and with wide regional variations [16–19]. The aim
of our study is to describe the demographic and genetic
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features of this group of neuromuscular diseases in Na-
varre for a 16-year period (2000–2015) and to estimate
the prevalence according to IMD subtype, age group and
geographical distribution.
Patients and methods
Observational retrospective study based on the identifi-
cation of adults and children with IMDs using all health
databases available within the regional health system
(from January 1, 2000 to December 31, 2015). The Na-
varre Ethics Research Committee approved this study.
The procedures followed are in accordance with the
Helsinki Declaration of 1975, as revised in 2000.
Study population
The study was conducted on a well-defined population
from the Navarre Community in Northern Spain (Fig. 1)
with an estimated population of 640,647 inhabitants as
per the 2016 census [20]. Most citizens are covered by
the Regional Public Health Service of Navarre - Osasun-
bidea, part of the Spanish National Health Service. Only
3.1% of the population has private o mixed health insur-
ance [21]. Navarre is organized in seven geographic
areas (Fig. 1) (Navarre 2000 Zoning) [22].
Diagnostic criteria
The study considered patients of any age, residents in
Navarre during 2000–2015, with a definitive diagnosis or
with high suspicion of suffering an IMD even without
confirmed genetic diagnosis. We distinguished two
groups of patients: 1) The definitive diagnosis of IMD
group included subjects with genetically confirmed diag-
nosis as proposed in the 2017 version of the gene table
of monogenic neuromuscular disorders [23] or with typ-
ical clinical phenotype consistent with a pathogenic mu-
tation verified within the pedigree or patients with
specific and well-correlated histopathological findings
even in the absence of genetic confirmation. 2) The un-
classified IMD group included patients with suspected
but undiagnosed genetic muscle disease according to the
phenotypes described by Harris et al. [24] following a
thorough analysis of the patient: a) congenital onset and
normal or mildly elevated creatine kinase (CK) levels; b)
adult onset proximal weakness with significantly elevated
CK and possible recessive inheritance; c) myopathy with
prominent contractures. Patients from the second group
did not meet the criteria of definitive IMD subtype as
shown in Table 1. Subjects with muscle channelopathy,
mitochondrial myopathies, female carriers of dystrophi-
nopathy or isolated hyperCKemia were excluded from
this study.
Genetic analysis
Blood was collected from patient after obtaining in-
formed consent. DNA was extracted using standard pro-
cedures from peripheral blood samples taken from all
patients. Appropriate genetic studies were performed in
each case.
Sequencing techniques after amplification of all coding
exons and adjacent areas of different genes associated to
inherited muscle disease (CAPN3, DYSF, SGCG, SGCA,
FKRP, ANO5, PABPN1, EMD, LMNA, GMPPB, GAA,
Fig. 1 Navarre is a region in northern Spain organized in seven geographic areas
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PYGM, CPT2, MYH-7, ACTA1, LDB3) were performed
to determine the DNA variants consistent in base
changes; substitutions, and small insertions and dele-
tions. First studies were carried out by Sanger sequen-
cing following diagnostic algorithms gene-to-gene,
while the implementation of the next generation se-
quencing (NGS) techniques in clinical diagnosis was
studied by groups or panels in different NGS plat-
forms. Bioinformatic tools were used to the alignment
of the sequences to human reference genome; and de-
tection, annotation and prioritization of variants.
DMD gene dosage analysis was determined by multi-
plex ligation-dependent probe amplification (MLPA).
The SALSA® MLPA® P034 DMD-1 and P035 DMD-2
(MRC-Holland, Amsterdam) were used for the detec-
tion of exon deletions or duplications in the DMD
gene while point mutations were identified by sequen-
cing studies.












characteristic clinical phenotype + a pathogenic mutation confirmed within the pedigree
Dystrophinopathies Genetic confirmation or,
DMD characteristic clinical phenotype + absence of dystrophin in Western blot
CMD Genetic confirmation or,
Dystroglycanopathies characteristic clinical phenotype + muscle biopsy with loss of α-dystroglycan [25]
Unclassified characteristic clinical phenotype with onset < 2 years + muscle biopsy with dystrophic pattern
Metabolic Myopathies
Glycogen storage disease Genetic confirmation or,
GSD-V characteristic clinical phenotype + increased serum CK +muscle biopsy with vacuoles with glycogen deposition and
absence of myophosphorylase activity [26]




Lipid storage disease Genetic confirmation
Congenital myopathies
Central core Genetic confirmation or,
clinical phenotype + muscle biopsy with cores with devoid of oxidative enzyme activity and type 1 fibre
predominance [27]
Centronuclear Genetic confirmation or,
clinical phenotype + muscle biopsy with central nuclei [28]
Myosin storage myopathy Genetic confirmation or,
clinical phenotype + muscle biopsy with sarcomeric aggregation of myosin rod filaments [29]
Nemaline myopathy Genetic confirmation or,
clinical phenotype + muscle biopsy with rod-like structures in muscle fibres [30]
Fibre type disproportion Genetic confirmation or,
clinical phenotype + muscle biopsy with type 1 fibre diameter at least 35–40% smaller than type 2 fibres diameter in
the absence of other structural abnormalities [31]
Myofibrillar myopathies Genetic confirmation
Distal myopathies Genetic confirmation or,
clinical phenotype + myopathic findings on muscle biopsy + myopathic findings on electromyography + magnetic
resonance imaging patterns [32]
Unclassified myopathies Congenital onset and normal or mildly elevated CK levels or,
adult onset proximal weakness + significantly elevated CK and possible recessive inheritance or,
myopathy + prominent contractures
FSHD Facioscapulohumeral muscular dystrophy, LGMD Limg girdle muscular dystrophy, OPMD Oculopharyngeal muscular dystrophy, EDMD Emery-Dreifuss
muscular dystrophy, DMD Duchenne muscular dystrophinopathy, CMD Congenital muscular dystrophy
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Myotonic dystrophy type l (DM-1) is caused by
(CTG)n repeat expansion in the 3′-untranslated region
of the DMPK gene. The sizing of this expansion was
done by conventional PCR, fragment-length analysis,
repeat-primed PCR, and fragment-length analysis.
The contraction of the D4Z4 repeat on chromosomes
4 is responsible of the facioscapulohumeral muscular
dystrophy type 1 (FSHD1). The size of the D4Z4 repeats
was determined by pulsed field gel electrophoresis
(PFGE) as previously described [33]. Facioscapulohum-
eral muscular dystrophy type 2 (FSHD2) was studied by
sequencing of SMCHD1 gene, which is involved in the
maintenance of D4Z4 methylation.
Variants of interest detected by sequencing were classi-
fied according to different databases and the published lit-
erature. Population databases: 1000 Genomes Project
(http://browser.1000genomes.org), Exome Variant Server
(http://evs.gs.washington.edu/EVS) and Exome Aggrega-
tion Consortium (http://exac.broadinstitute.org/). Disease
databases: Human Gene Mutation Database (http://www.
hgmd.org), Leiden Open Variation Database (http://www.
lovd.nl) and ClinVar (http://www.ncbi.nlm.nih.gov/clin-
var). In silico approach was carried out to assess the
pathogenicity of new variants using different tools as Mu-
tation Taster (http://www.mutationtaster.org).
Methodological validation and segregation studies
were performed by direct sequencing (ABI 3500 Genetic
Analyzer, Applied Biosystems, Warrington, UK) using
Big Dye Terminator Cycle Sequencing Kit (Applied Bio-
systems, Warrington, UK). The subsequent analysis was
done with SeqScape software (Thermo Fisher).
Case ascertainment sources
Case ascertainment was achieved using multiple overlap-
ping sources:
(1) Navarre’s Minimum Basic Data Set (MBDS), a re-
gional computer-based database system designed to collect
demographic, clinical and administrative data on discharges,
including both private and publicly funded hospitals. Inter-
national Classification of Diseases (Ninth Revision, Clinical
Modification, ICD-9-CM), including 271.0, 272.7, 359.0,
359.1, 359.2, 359.21, 359.22, 359.29, 359.89 and 359.9, were
used to search patients affected by IMDs [34].
(2) Electronic Clinical Records in Primary Care
(ECRPC) of Navarre‘s Public Health System, a regional
healthcare information system that allows registering
demographic, clinical and administrative data on primary
care episodes. International Classification of Primary Care,
second edition (ICPC-2) was used to encode healthcare
episodes [35]. In Navarre, the ECRPC system proposes
several literal descriptors linked to the ICPC-2 codes for
general practitioners, including muscular dystrophy and
unspecified myopathy for code N99 (Neurological disease,
other), which we used for selecting the patients [36].
(3) Temporary Occupational Disability Registry of Na-
varre, designed to collect data on sick leaves. ICD-9-CM
codes, including the aforementioned ones, were used to
select patients affected by IMDs [36].
(4) Records from the Medical Genetics Service allowed
selecting patients that were being monitored for IMD
suspicion. Several keywords enabled us to detect these
patients, depending on the reason for the request of the
genetic study.
(5) The Congenital Anomalies and Hereditary Diseases
Registry of Navarre, a population-based listing affiliated
member to EUROCAT [37]. Keyword diagnostic
searches were used to select patients suffering IMDs.
(6) Navarre’s Mortality Statistics in which the primary
cause of death from the Medical Death Certificate [38,
39] is listed. We used the ICD-10 codes, including
G71.0, G71.1, G71.2, G71.3, G71.8, G71.9, G72.8, G72.9
and G73.6 to identify IMD patients.
(7) Electronic Clinical Records from the Neurology
Services of Navarre’s public hospitals. Patients with
IMDs were detected using keyword diagnostic searches.
The information from the various data sources showed
all potential diagnoses of IMDs. This information was
cross-checked with the databases for duplication. Next, a
neuromuscular neurologist verified the diagnosis of each
double-checked case based on the inclusion and exclu-
sion criteria for each condition.
We collected the following information: type of IMD,
gender, date of birth, date of death, place of residence
on January 1, 2016, and genetic diagnosis.
Data analysis
January 1, 2016 was the date chosen for estimating
prevalence. The population at risk is defined as the resi-
dents of Navarre as per the Spanish National Statistics
Institute and the Statistics Institute of Navarre [20] (Na-
varre population = 640,647). The 2016 prevalence rates
are expressed as cases/100,000 inhabitants. An overall
prevalence was estimated globally and by gender, age
and geographical area within Navarre. Descriptive results
are presented as frequencies and proportions. Poisson
distribution was assumed to estimate CI 95% for preva-
lence and proportions rates. For inter-group proportion
comparisons, the Pearson Chi-square test was applied.
Statistical analyses were conducted using the OpenEpi
program [40].
Results
The search strategy allowed us to retrieve 2729 potential
cases after the removal of duplicates, from which 1899
required diagnostic verification (Fig. 2). Five hundred
thirteen cases fulfilled the diagnostic standards listed in
Table 1, representing 27.01% of the initial potential
cases: 281 (54.77%) males and 232 (45.22%) females
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(1.21:1). Twenty-six different disease entities were de-
tected. During the study period, 23.20% of the subjects
(62 males and 57 females) died.
Genetic and other diagnostic standards
From the 513 identified IMDs, 464 were definitive and
49 unclassified IMDs, respectively. Concerning the de-
finitive IMD cases, 329 (70.90%) were genetically veri-
fied, 113 (24.35%) had a clinical phenotype with a
pathogenic mutation confirmed with the pedigree, and
in 22 (4.74%), characteristic muscle biopsy pathogenic
features were found (Table 2).
Genetic descriptions of dystrophinopathies are detailed
in Table 3, while the rest of IMDs can be seen Table 4.
Prevalence
On 1 January 2016, 378 subjects with IMDs (56.61%
male and 43.39% female) were residents of Navarre, im-
plying a prevalence of 59.00/100,000 inhabitants (CI
95%; 53.35–65.26) (Table 5). DM-1 represented the most
common IMDs, with a prevalence of 35.90/100,000 (CI
95%; 31.55–40.85), followed by facioscapulohumeral
muscular dystrophy (FSHD) and limb girdle muscular
dystrophy 2A (LGMD2A) affecting 5.15/100,000 (95%
CI; 3.67–7.23) and 2.5/100,000 (CI 95%; 1.54–4.05) in-
habitants, respectively. There were 11 cases of dystrophi-
nopathies, with Duchenne muscular dystrophy (DMD)
present in 0.94/100,000 (CI 95%; 0.43–2.04) and Becker
muscular dystrophy (BMD) in 0.78/100,000 (CI 95%;
0.33–1.83) individuals. Congenital myopathy, congenital
muscular dystrophy (CMD), myofibrillar myopathy, and
metabolic myopathy were observed in 1.25 (CI 95%;
0.63–2.46), 0.62 (CI 95%; 0.24–1.60), 0.78 (CI 95%;
0.33–1.83), and 1.71 (CI 95%; 0.95–3.07) per every 100,
000 inhabitants, respectively.
The range of age was 1–89 years, with a mean age of
46.93 years (SD 17.77) (45.70 (SD 19.01) for males and 48.54
(SD 15.93) for females). The highest age-specific prevalence
(Table 6) was obtained for the age range between 45 to 54
years, with a prevalence of 91.32/100,000 (CI 95%;
74.31–112.2) subjects. Prevalence was statistically significant
higher in males in comparison to females for the following
groups: under 15, 25 to 34, and 75 to 84 years of age.
The prevalence of IMDs differed notably by geo-
graphic areas, with the highest estimate found for the
region of Tierra Estella (97.15/100,000 subjects),
significantly higher in comparison to all other areas, ex-
cept for the Eastern Middle area of Navarre. Figure 3
shows the geographical distribution of IMD prevalence.
Discussion
In this study, we present data on Inherited Muscle Dis-
eases compiled over a 16-year period from different
healthcare information systems. Our results show a
prevalence of IMDs in Navarre of 59.00/100,000 sub-
jects, being higher in males than in females, highest for
Fig. 2 Flow-chart of potential cases of inherited muscle disease in Navarre, 2000–2015
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the 45 to 54 years age range, and with remarkable geo-
graphical variability. DM-1, FSHD, and LGMD2A are
the most common subtypes IMDs.
We believe the non-inclusion in the analyses of the
unclassified group of IMDs may underestimate the real
prevalence, bearing in mind that each case was thor-
oughly assessed by a specialized neurologist. To avoid
selection biases when comparing with other studies, we
also present prevalence with a confirmed genetic diagno-
sis: 50.10/100,000 (CI 95%; 44.92–55.89), which remains
to be high in comparison to the results published
elsewhere [5]. Four hundred and forty two cases
(86.16%) of IMDs had a confirmed genetic diagnosis.
Epidemiological studies of neuromuscular diseases
Prevalence studies require exhaustiveness. The lack of
specific registries and the absence of diagnostic code veri-
fications [9, 41–43] could lead an IMD selection bias [15].
Moreover, for comparability purposes stringent inclusion
criteria is mandatory.
Aiming to avoid these intrinsic limitations in preva-
lence studies, for this study we used seven case
Table 2 Inherited Muscle Disease subtype and diagnostic standard used
HM Type Diagnostic standard N° of cases
DM-1 Genetic confirmation 225
Clinical phenotype + pedigree 97
FSHD Genetic confirmation 32
Clinical phenotype + pedigree 9
LGMD2 Genetic confirmation 27
Clinical phenotype + pedigree 4
LGMD2C Clinical phenotype + muscle biopsy 2
OPMD Genetic confirmation 5
EDMD Genetic confirmation 5
DMD Genetic confirmation 13
Clinical phenotype + muscle biopsy 2
BMD Genetic confirmation 7
Dystroglycanopathies Genetic confirmation 1
Clinical phenotype + pedigree 1
Clinical phenotype + muscle biopsy 1
Unclassified CMD Clinical phenotype + muscle biopsy 2
GSD-II Genetic confirmation 2
GSD-V Genetic confirmation 4
Clinical phenotype + muscle biopsy 2
Unclassified GSD Clinical phenotype + muscle biopsy 2
Lipid storage disease Genetic confirmation 1
Central Core Clinical phenotype + muscle biopsy 2
Myosin storage myopathy Genetic confirmation 2
Clinical phenotype + muscle biopsy 1
Nemaline myopathy Genetic confirmation 1
Clinical phenotype + muscle biopsy 2
Fibre type disproportion Clinical phenotype + muscle biopsy 3
Zaspopathy Genetic confirmation 4
Clinical phenotype + pedigree 2
Distal myopathies Clinical phenotype + magnetic resonance imaging patterns 3
DM-1 Myotonic dystrophy type 1, FSHD Facioscapulohumeral muscular dystrophy, LGMD Limb girdle muscular dystrophy, OPMD Oculopharyngeal muscular
dystrophy, EDMD Emery-Dreifuss muscular dystrophy, DMD Duchenne muscular dystrophinopathy, CMD congenital muscular dystrophy, BMD Becker muscular
dystrophinopathy, CMD Congenital muscle dystrophy, GSD Glycogen storage disease.
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ascertainment sources at different healthcare levels and
made an exhaustive verification of the diagnoses with
well-defined inclusion and exclusion criteria.
Data sources
This study was affected by the lack of disease codifica-
tion specificity in the Spanish healthcare information
systems for IMDs. Only 27.01% of the cases initially
identified with the selected codes and keywords met the
inclusion criteria for IMD. Thus, it is essential to review
and verify the diagnosis procedures to obtain quality
data for this type of epidemiological.
The introduction of population-based registries spe-
cific for neuromuscular and/or other rare diseases, in-
cluding specific codes, would be of great help in future
studies.
Overall and disease-specific prevalence data
Our study shows a prevalence of IMDs of 59.00/100,000
(CI 95%; 53.35–65.26) inhabitants for Navarre. Compari-
sons with prevalence data from other regions is compli-
cated due to the lack of methodological homogeneity
and because most studies focus on a specific IMD.
Emery [44] reports a global prevalence of hereditary
neuromuscular disorders of 1/3500 inhabitants
(prevalence 28.57/100,000), including spinal muscular
atrophy and hereditary sensitive-motor neuropathy. In
another study carried out in the UK, a prevalence of
IMDs of 37/100,000 people is described for a Northern
region of England [6]. More recently, Theadom et al. [5]
describe a prevalence of 22.3/100,000 inhabitants of all
genetic muscle disorders in New Zealand, with higher
incidence in subjects of European ancestry.
To the best of our knowledge, this is the first time a
study includes all types of IMDs in a Spanish region.
The subtype of IMD with the highest number of cases
in our series was DM-1 (58.87% of the cases) with a
prevalence of 35.90/100,000 (CI 95%; 31.55–40.85). In
previous works, the prevalence of this particular condi-
tion showed wide geographical variations. The lowest re-
ported for Japan (0.2/100,000) [8] up to 172/100,000 for
Quebec [45] due to the founder effect. Regarding data
from Spanish regions, Burcet et al. [18] found 10.9/100,
000 cases of DM-1 in Majorca, while Munain et al. [16]
reported 26.5/100,000 in Guipuzcoa. These regional var-
iations could indicate a possible underestimation of
prevalence linked to the used methodology.
However, we believe that despite the used method-
ology, the high prevalence of DM-1 in Navarre could be
explained by a possible founding effect, similar to that
reported for Guipuzcoa [16], considering that both
Table 3 Genetically confirmed dystrophinopathies
Case number Dystrophinopathy type Gene Mutation type Position and/or sequence variation
1 DMD DMD Deletion Exons 44–55
2 DMD DMD Deletion Exons 18–28
3 DMD DMD Duplication Exons 18–48
4 DMD DMD Deletion Exons 49 y 50
5 DMD DMD Deletion Exons 45–53
6 DMD DMD Deletion Exons 45–49
7 DMD DMD Duplication Exon 3
8 DMD DMD SNV c.353G > A, p.Trp118a
9 DMD DMD Deletion Exon 43




14 BMD DMD Deletion Exon 52
15 BMD DMD Deletion Intron 49
16 BMD DMD Deletion Exons 3–7
17 BMD DMD Deletion Exons 45–55
18 BMD DMD Duplication Exon 2
19b BMD
20b BMD
aNo mutation identified. Negative deletion/duplication study. Positive familial segregation
bEvidence of genetic confirmation in the clinical record; no access to the identified mutation
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Table 4 Pathogenic molecular defect of each genetically confirmed IMD
Muscular disease type Gene Mutation type Sequence variation Position Zygosity Cases, n Families, n
Muscular dystrophy
MD1 DMPK Expanded CTG (> 40) 3′-UTR 225 116
FSHD1 DUX Deletion D4Z4 25 21
FSHD2 SMCHD1 SNV c.5602C > T Exon 45 Het 6 1
SMCHD1 SNV c.2329A > T Exon 18 Het 1 1












LGMD2B DYSF SNV c.895G > A Exon 9 Hom 1 1
LGMD2C SGCG SNV c.848G > A Exon 8 Hom 2 2
LGMD2D SGCA SNV c.293G > A Exon 3 Hom 1 1
LGMD2I FKRP SNV c.826C > A Exon 4 Hom 1 1
LGMD2L ANO5 Frameshift variant c.1627dupA Exon 15 Hom 1 1























OPMD PABPN1 Expanded GCN (> 10) Exon 1 5 4
Emerin EDMD EMD Complete deletion 1 1
Lamin EDMD LMNA SNV c.1130G > A Exon 6 Het 2 1
LMNA SNV c.215G > T Exon 1 Het 1 1
LMNA SNV c.65C > A Exon 1 Het 1 1






































Lipid storage disease CPT2 SNV
SNV
c.359A > G







Myosin storage MYH-7 SNV c.5533C > T Exon 37 Het 1 1
MYH-7 SNV c.1314G > A Exon 14 Het 1 1
Nemaline ACTA1 SNV c.808G > C Exon 5 Het 1 1
Myofibrillar myopathy
Zaspopathy LDB3 SNV c.494C > T Exon 5 Het 4 1
a Evidence of genetic confirmation in the clinical record; no access to the identified mutation
Hom Homozygous, Het Heterozygous, SNV Single Nucleotide Variation
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regions share cultural and background similarities.
Moreover, the management of the patients by multidis-
ciplinary teams in recent years may have a positive effect
on survival by lowering the complications.
Prevalence of LGMD also differs between studies.
Theadom’s review [15] reports a global prevalence of
LGMD of 0.9/100,000 inhabitants. Here, we show a
higher prevalence of LGMD (4.21/100,000) (CI of 95%
2.90–6.13), closer to the 4.8/100,000 estimated by Far-
deu et al. [46] in a tiny community in Reunion, where
high rates of endogamy have been described. In Spain, a
study by Urtasun et al. in the Basque Country found a
Table 5 Inherited muscle disease prevalence in Navarre by January 1, 2016
Type of myopathy Cases, n PRx105 (CI 95%) PR male PR female p Mean age (SD)
Muscular dystrophy 312 48.70 (43.59–54.41) 53.80 43.67 0.066 46.43 (17.14)
Myotonic dystrophy 1 230 35.90 (31.55–40.85) 36.18 35.63 0.906 47.06 (15.39)
FSHD 33 5.15 (3.67–7.23) 6.92 3.41 0.052 55.51 (14.44)
FSHD1 27 4.21 (2.90–6.13) 5.98 2.48 0.320 58.15 (13.06)
FSHD2 6 0.94 (0.43–2.04) 0.94 0.93 0.985 43.67 (15.54)
LGMD2 27 4.21 (0.90–6.13) 5.03 3.41 0.325 45.04 (17.67)
LGMD2A 16 2.50 (1.54–4.05) 2.52 2.48 0.975 43.81 (14.63)
LGMD2B 1 0.16 (0.03–0.88) 0.31 0.00 0.496 56 (−)
LGMD2C 3 0.47 (0.16–1.38) 0.94 0.00 0.122 21.33 (24.45)
LGMD2D 1 0.16 (0.03–0.88) 0.00 0.31 0.503 46 (−)
LGMD2I 1 0.16 (0.03–0.88) 0.31 0.00 0.496 53 (−)
LGMD2L 5 0.78 (0.33–1.83) 0.94 0.62 0.675 59.20 (16.51)
OPMD 2 0.31 (0.08–1.14) 0.63 0.00 0.246 72 (15,56)
EDMD 5 0.78 (0.33–1.83) 0.94 0.62 0.675 41.80 (19.32)
Emerin EDMD 1 0.16 (0.03–0.88) 0.31 0.00 0.496 19 (−)
Lamin EDMD 4 0.62 (0.24–1.60) 0.63 0.62 0.988 47.5 (16.76)
Dystrophinopathy 11 1.71 (0.95–3.07) 3.46 0.00 0.000 18.73 (18.26)
DMD 6 0.94 (0.43–2.04) 1.89 0.00 0.015 8.33 (4.80)
BMD 5 0.78 (0.33–1.83) 1.57 0.00 0.030 31.2 (21.18)
CMD 4 0.62 (0.24–1.60) 0.63 0.62 0.988 13.25 (6.34)
Glycosylation disorder 3 0.47 (0.16–1.38) 0.63 0.31 0.616 10.67 (4.51)
Unclassified CMD 1 0.16 (0.03–0.88) 0.00 0.31 0.503 21 (−)
Metabolic myopathies 11 1.71 (0.95–3.07) 2.52 0.93 0.139 45.91 (19.13)
Glycogen storage 10 1.56 (0.85–2.87) 2.52 0.62 0.062 49.10 (16.80)
GSD-II 2 0.31 (0.08–1.14) 0.63 0.00 0.246 43 (12.73)
GSD-V 6 0.94 (0.43–2.04) 1.26 0.62 0.442 5.15 (20.83)
Unclassified 2 0.31 (0.08–1.14) 0.63 0.00 0.246 48 (9.90)
Lipid storage disease 1 0.16 (0.03–0.88) 0.00 0.31 0.503 14 (−)
Congenital myopathy 8 1.25 (0.63–2.46) 2.20 0.31 0.037 36.12 (14.20)
Central Core 2 0.31 (0.08–1.14) 0.63 0.00 0.246 22.50 (24.75)
Myosin storage myopathy 3 0.47 (0.16–1.38) 0.94 0.00 0.122 44.67 (9.07)
Fibre type disproportion 3 0.47 (0.16–1.38) 0.63 0.31 0.616 36.67 (4.62)
Distal myopathy 3 0.47 (0.16–1.38) 0.63 0.31 0.616 65.67 (17.78)
Zaspopathy 5 0.78 (0.33–1.83) 1.26 0.31 0.212 63.40 (4.88)
Unclassified myopathy 39 6.09 (4.45–8.32) 6.92 5.27 0.402 59.92 (21.86)
Total 378 59.00 (53.35–65.26) 67.33 50.80 0.006 46.93 (17.77)
SD Standard deviation.
OPMD Oculopharyngeal muscular dystrophy, EDMD Emery-Dreifuss muscular dystrophy, DMD Duchenne muscular dystrophinopathy, CMD Congenital muscular
dystrophy, BMD Becker muscular dystrophinopathy, CMD congenital muscle dystrophy, GSD glycogen storage disease.
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prevalence of 6.9/100,000 [17]. The most common form
of LGMD is LGMD2A in the Basque Country and in
our study, with over 50% of LGMD cases (59.26 and
61.29%, respectively). Both studies detected a high fre-
quency of the c.2362_2363delinsAG/TCATCT mutation
in exon 22 of the CAPN3 gene, which has been observed
primarily in chromosomes of Basque natives and more
exceptionally in individuals from other parts of the
world [17]. In our study, this pathogenic variant is
present in 100% of the LGMD2A.
The prevalence of dystrophinopathies in our study is
0.94/100,000 for DMD and 0.78/100,000 for BMD.
These values are lower than those reported elsewhere.
The meta-analysis conducted by Mah et al. [47] showed
an estimated prevalence of 4.78/100,000 (CI 95%; 1.94–
11.81) for DMD and 1.53/100,000 (CI 95%; 0.26–8.94)
for BMD. The study performed in New Zealand [5]
shows a prevalence of DMD of 2.45/100,000 (CI 95%;
2.01–2.98) and 1.67/100,000 (CI 95%; 1.32–2.12) for
BMD with ethnic differences. However, some studies
Fig. 3 Geographical distribution of prevalence (per 100,000) of inherited muscle disease in Navarre









< 15 21.87 (14.44–33.11) 10.20 (4.36–23.87) 32.97 (20.59–52.80) 0.015
15–24 41.84 (28.56–61.30) 42.84 (25.04–73.29) 40.89 (23.9–69.95) 0.906
25–34 48.99 (35.39–67.82) 21.93 (11.11–43.27) 75,68 (52.37–109.40) 0.000
35–44 72.13 (57.64–90.26) 70.53 (50.95–97.62) 73.63 (54.08–100.24) 0.853
45–54 91.32 (74.31–112.2) 93.36 (69.79–124.92) 89.37 (66.81–119.6) 0.836
55–64 91.50 (72.56–115.40) 82.69 (58.58–116.7) 100.27 (73.37–137.20) 0.421
65–74 59.40 (42.92–82.23) 57.51 (36.38–90.9) 61.43 (38.86–97.09) 0.844
75–84 39.08 (24.06–63.47) 21.42 (9.15–50.14) 62.48 (34.9–111.90) 0.044
≥85 23.38 (9.99–54.73) 13.92 (3.81–50.76) 42.73 (14.53–125.62) 0.245
Total 59.00 (53.35–65.26) 50.80 (43.46–59.36) 67.33 (58.9–76.97) 0.006
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show a prevalence of DMD below 2/100,000 [43, 48].
We believe that the poor exploitation of electronic clin-
ical records from Paediatric Services did not cause a
biased estimation of dystrophinopathies in our study.
We observed higher prevalence of IMDs in men than
in women. This difference could be due to the X-linked
inheritance of DMD and BMD. However, we also ob-
served significant differences in the congenital myop-
athies subgroup, with higher prevalence in men.
Furthermore, there was higher prevalence in men in the
following age groups: under 15, 25 to 34, and 75 to 84
years of age. In the under 15 group, the X-linked nature
of DMD could explain this elevated prevalence [49]. In
the other two age groups, the IMD subtypes differ
greatly and we have clear explanation for the gender dif-
ferences. The highest prevalence of IMDs is seen for the
working age group (between 35 to 64 years) probably
contributing to huge socio-economic burden. Further
studies should be designed to analyse the impact these
conditions have on the economy.
We also detected prevalence geographical distribution
differences within Navarre, which may be useful when
planning resources. The highest prevalence of IMDs was
determined for Tierra Estella Area (PR 97.15 with IC
95% 70.19–134.50) (Fig. 3).
Unclassified inherited muscle disease
In the course of this study, we identified 49 patients
(9.55%) with a potential genetic cause for their muscle
disease. During the period of our study (2000 to 2015),
most genetic diagnosis followed the gene-by-gene testing
strategy based on their phenotype. Current availability of
next-generation sequencing is changing the diagnostic
approach, increasing confirmed genetic diagnosis, as well
as the identification of new IMD-associated mutations.
Thirty-nine patients remained alive by the end of the
study (December 2015) and from the end of the study to
the present time genetic IMD confirmation was obtained
for 18 (46, 15%).
Study limitations
Although the study has been exhaustive, poor exploit-
ation of the electronic clinical records in Paediatric Ser-
vices could bias childhood IMD data, e.g., DMD.
However, we believe that the exploitation of other data
sources counteracts this deficiency, consequently with
mild underestimation of IMD prevalence in this age
group.
Conclusions
The prevalence of IMDs in Navarre is 59.00/100,000 in-
habitants CI (53.35–65.26), which is a high number if
compared with data reported for other geographical re-
gions. If only patients with confirmed genetic diagnosis
are considered, the prevalence is 50.10/100,000 (CI 95%;
44.92–55.89). The high prevalence of DM-1 (35.90/100,
000 with CI 31.55–40.85) and of LGMD2A (2.5/100,000
with CI 1.54–4.05) could suggest the existence of a
founding effect in Navarre. Genetic confirmation was
available in 442 (86.16%) of IMD patients in our region.
Our population study has a high sensitivity because all
possible sources of information have been used. The lack
of specificity of disease coding in our health information
system for IMDs has made the study difficult and has
forced us to review the clinical data of each case to verify
the diagnosis. It is essential to implement specific popu-
lation based registries for neuromuscular and other rare
diseases, taking into account the heterogeneity of these
disorders.
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